Pulmonary Hypertension News Forums › Forums › Research and Development › PH Patients Prefer Yutrepia Over Tyvaso in INSPIRE Study

Tagged: , , ,

  • Research & Development

    PH Patients Prefer Yutrepia Over Tyvaso in INSPIRE Study

    Posted by jen-cueva on August 23, 2022 at 11:23 am

    Yutrepia, an inhaled formulation of treprostinil, was generally well tolerated and improved the quality of life for people with PH in the Phase 3 INSPIRE clinical trial.

    Here are some of the highlights from this exciting article.

    *The dry powder form of treprostinil.
    *Safety, dosing, and tolerability confirmed
    *Convenient
    *Frequency of side effects markedly lower in those who switched from Tyvaso
    *Final decision for FDA approval later this year

    You can read more here.

    It’s always inspiring to read about promising clinical trials and improving the quality of life for those within the PH community. Do you have any takeaways from this article?

    jen-cueva replied 1 year, 8 months ago 0 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .